Patents by Inventor Jerome B. Zeldis

Jerome B. Zeldis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20040087546
    Abstract: Methods of treating, preventing and/or managing a myeloproliferative disease are disclosed. Specific methods encompass the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent, and/or the transplantation of blood or cells. Particular second active agents are capable of suppressing the overproduction of hematopoietic stem cells or ameliorating one or more of the symptoms of a myeloproliferative disease. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
    Type: Application
    Filed: April 11, 2003
    Publication date: May 6, 2004
    Inventor: Jerome B. Zeldis
  • Publication number: 20040087558
    Abstract: Methods of treating, preventing, modifying and managing various types of pain are disclosed. Specific methods comprise the administration of a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent and/or surgery, psychological or physical therapy. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
    Type: Application
    Filed: October 23, 2003
    Publication date: May 6, 2004
    Inventors: Jerome B. Zeldis, Herbert Faleck, Donald C. Manning
  • Publication number: 20040087642
    Abstract: The present invention relates to methods for treating, preventing, managing and/or modifying pain, comprising administering an effective amount of a JNK Inhibitor to a patient in need thereof. Specific embodiments encompass the administration of a JNK Inhibitor, alone or in combination with a second active agent and/or surgery or physical therapy. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
    Type: Application
    Filed: October 23, 2003
    Publication date: May 6, 2004
    Inventors: Jerome B. Zeldis, Herbert Faleck, Donald C. Manning
  • Publication number: 20040034084
    Abstract: The present invention relates to methods useful for the treatment or prevention of disease-related wasting. The methods of the invention comprise the administration of an effective amount of a JNK Inhibitor. In one embodiment, the disease is HIV, AIDS, cancer, end-stage renal disease, kidney failure, chronic heart disease, obstructive pulmonary disease or tuberculosis. The methods can further comprise the administration of a therapeutic or prophylactic agent useful for the treatment or prevention of HIV, AIDS, cancer, end-stage renal disease, kidney failure, chronic heart disease, obstructive pulmonary disease, chronic infectious diseases (e.g., osteoarthritis and bacterial endocarditis), chronic inflammatory diseases (e.g., scleroderma and mixed connective tissue disease) or tuberculosis.
    Type: Application
    Filed: May 22, 2003
    Publication date: February 19, 2004
    Applicant: Celgene Corporation
    Inventor: Jerome B. Zeldis
  • Publication number: 20040028660
    Abstract: The present invention provides methods of modulating mammalian, particularly human, stem cell and progenitor cell differentiation to regulate and control the differentiation and maturation of these cells along specific cell and tissue lineages. The methods of the invention relate to the use of certain small organic molecules to modulate the differentiation of stem cell populations along specific cell and tissue lineages, particularly embryonic-like stem cells originating from a postpartum placenta or stem cells isolated form sources such as cord blood. The invention also relates to the treatment or prevention of myelodysplastic syndrome or myeloproliferative syndrome, or symptoms thereof, comprising administration of JNK or MKK inhibitors, alone or in combination, as well as with or without the use of unconditioned cells or cells conditioned in accordance with other aspects of the invention.
    Type: Application
    Filed: May 30, 2003
    Publication date: February 12, 2004
    Applicants: Anthrogenesis Corporation, Celgene Corporation
    Inventors: Robert J. Hariri, David I. Stirling, Jerome B. Zeldis
  • Publication number: 20040029832
    Abstract: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
    Type: Application
    Filed: May 15, 2003
    Publication date: February 12, 2004
    Inventor: Jerome B. Zeldis
  • Publication number: 20030232857
    Abstract: Chronic bolus administration of D-threo methylphenidate is provided. The administration of the D-threo isomer eliminates adverse side effects associated with the DL racemate, and provides improved effectiveness. The compositions and methods of the invention are useful in treating nervous system disorders including attention deficit disorder, attention deficit hyperactivity disorder, and cognitive decline associated with systemic diseases such as acquired immunodeficiency syndrome.
    Type: Application
    Filed: March 24, 2003
    Publication date: December 18, 2003
    Inventors: Maghsoud M. Dariani, Andrew L. Zeitlin, Jerome B. Zeldis
  • Publication number: 20030149025
    Abstract: This invention relates to methods for using benzopyranones, or their pharaceutically acceptable salts, for treating or preventing a primary brain cancer or a brain metastasis.
    Type: Application
    Filed: September 30, 2002
    Publication date: August 7, 2003
    Applicant: Signal Pharmaceuticals, Inc.
    Inventor: Jerome B. Zeldis
  • Patent number: 6602887
    Abstract: Chronic bolus administration of D-threo methylphenidate is provided. The administration of the D-threo isomer eliminates adverse side effects associated with the DL racemate, and provides improved effectiveness. The compositions and methods of the invention are useful in treating nervous system disorders including attention deficit disorder, attention deficit hyperactivity disorder, and cognitive decline associated with systemic diseases such as acquired immunodeficiency syndrome.
    Type: Grant
    Filed: May 24, 2001
    Date of Patent: August 5, 2003
    Assignee: Celegene Corporation
    Inventors: Maghsoud M. Dariani, Andrew L. Zeitlin, Jerome B. Zeldis
  • Publication number: 20020198234
    Abstract: In one aspect, the present invention is directed to methods for treating fatigue, neurobehavioral slowing and other cognitive disorders and defects due to cancers and treatments associated with cancers, and similar conditions. In a further aspect, the present invention is directed to methods for treating disorders related to menopause, including executive function defects. The methods involve the administration of a composition comprising D-threo methylphenidate that is substantially free of L-threo methylphenidate and of erythro forms of methylphenidate.
    Type: Application
    Filed: July 16, 2002
    Publication date: December 26, 2002
    Applicant: WOODCOCK WASHBURN LLP
    Inventors: Jerome B. Zeldis, Herbert J. Faleck, Vikram Khetani, Andrew L. Zeitlin, Magsoud M. Dariani, David I. Sterling
  • Patent number: 6486177
    Abstract: In one aspect, the present invention is directed to methods for treating fatigue, neurobehavioral slowing and other cognitive disorders and defects due to cancers and treatments associated with cancers, and similar conditions. In a further aspect, the present invention is directed to methods for treating disorders related to menopause, including executive function defects. The methods involve the administration of a composition comprising D-threo methylphenidate that is substantially free of L-threo methylphenidate and of erythro forms of methylphenidate.
    Type: Grant
    Filed: July 12, 2001
    Date of Patent: November 26, 2002
    Assignee: Celgene Corporation
    Inventors: Jerome B. Zeldis, Herbert Faleck, Vikram Khetani
  • Publication number: 20020054899
    Abstract: Methods and compositions for the prevention and treatment of all forms of atherosclerosis are described. Administration of compounds such as thalidomide, its analogs, hydrolysis products, metabolites, derivatives and precursors as well as additional compounds capable of inhibiting tumor necrosis factor &agr; (TNF-&agr;) are used in the invention.
    Type: Application
    Filed: December 11, 2000
    Publication date: May 9, 2002
    Inventor: Jerome B. Zeldis
  • Publication number: 20020035090
    Abstract: This invention relates to compositions comprising thalidomide and another anti-cancer drug which can be used in the treatment or prevention of cancer. Preferred anti-cancer drugs are topoisomerase inhibitors. A particular composition comprises thalidomide, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, and irinotecan. The invention also relates to methods of treating or preventing cancer which comprise the administration of a thalidomide and another anti-cancer drug to a patient in need of such treatment or prevention. The invention further relates to methods of reducing or avoiding adverse side effects associated with the administration of chemotherapy or radiation therapy which comprise the administration of thalidomide to a patient in need of such reduction or avoidance.
    Type: Application
    Filed: May 14, 2001
    Publication date: March 21, 2002
    Inventors: Jerome B. Zeldis, Andrew L. Zeitlin, Sol Barer
  • Publication number: 20020022640
    Abstract: In one aspect, the present invention is directed to methods for treating fatigue, neurobehavioral slowing and other cognitive disorders and defects due to cancers and treatments associated with cancers, and similar conditions. In a further aspect, the present invention is directed to methods for treating disorders related to menopause, including executive function defects. The methods involve the administration of a composition comprising D-threo methylphenidate that is substantially free of L-threo methylphenidate and of erythro forms of methylphenidate.
    Type: Application
    Filed: July 12, 2001
    Publication date: February 21, 2002
    Inventors: Jerome B. Zeldis, Herbert Faleck, Vikram Khetani
  • Publication number: 20010041717
    Abstract: Chronic bolus administration of D-threo methylphenidate is provided. The administration of the D-threo isomer eliminates adverse side effects associated with the DL racemate, and provides improved effectiveness. The compositions and methods of the invention are useful in treating nervous system disorders including attention deficit disorder, attention deficit hyperactivity disorder, and cognitive decline associated with systemic diseases such as acquired immunodeficiency syndrome.
    Type: Application
    Filed: May 24, 2001
    Publication date: November 15, 2001
    Applicant: CELGENE CORPORATION
    Inventors: Maghsoud M. Dariani, Andrew L. Zeitlin, Jerome B. Zeldis
  • Patent number: 6255325
    Abstract: Chronic bolus administration of D-threo methylphenidate is provided. The administration of the D-threo isomer eliminates adverse side effects associated with the DL racemate, and provides improved effectiveness. The compositions and methods of the invention are useful in treating nervous system disorders including attention deficit disorder, attention deficit hyperactivity disorder, and cognitive decline associated with systemic diseases such as acquired immunodeficiency syndrome.
    Type: Grant
    Filed: June 21, 1999
    Date of Patent: July 3, 2001
    Assignee: Celgene Corporation
    Inventors: Maghsoud M. Dariani, Andrew L. Zeitlin, Jerome B. Zeldis
  • Patent number: 5984887
    Abstract: A method of treating infections of mononuclear blood cells, other than retroviral infections, is disclosed. A method of modulating the function of monocytes is also disclosed. The method involves the treatment of a patient's blood with a photoactivatable compound followed by ultra violet light-activation of the photoactivatable compound. The blood treated as such is returned to the patient in a process known as extracorporeal photopheresis. Monocyte function is modulated by this treatment.
    Type: Grant
    Filed: March 26, 1997
    Date of Patent: November 16, 1999
    Assignee: Therakos, Inc.
    Inventors: Susan N. McLaughlin, Bruce C. Stouch, Jerome B. Zeldis
  • Patent number: 5922736
    Abstract: Chronic bolus administration of D-threo methylphenidate is provided. The administration of the D-threo isomer eliminates adverse side effects associated with the DL racemate, and provides improved effectiveness. The compositions and methods of the invention are useful in treating nervous system disorders including attention deficit disorder, attention deficit hyperactivity disorder, and cognitive decline associated with systemic diseases such as acquired immunodeficiency syndrome.
    Type: Grant
    Filed: September 29, 1997
    Date of Patent: July 13, 1999
    Assignee: Celegene Corporation
    Inventors: Maghsoud M. Dariani, Andrew L. Zeitlin, Jerome B. Zeldis
  • Patent number: 5073481
    Abstract: An assay to detect the presence of live hepatitis viruses in vitro. Bone marrow cells of leukemic cell line cells are exposed to a body fluid or biological preparation to be tested and the cells are placed in suspension. When using bone marrow cells, growth factors to the bone marrow stem cells are added. It has been determined that presence of a live hepatitis virus suppresses the growth of colonies of the stem cells. Therefore, if the number of colonies growing in the mixture are less than that number present in a culture of cells exposed to a sample that has been determined to contain no live virus, live hepatitis virus is present in the sample tested. The assay is particularly useful to determine the presence of live hepatitis B virus in a vaccine.
    Type: Grant
    Filed: November 30, 1989
    Date of Patent: December 17, 1991
    Assignee: Beth Israel Hospital Association
    Inventors: Jerome B. Zeldis, Robert P. Gale, Howard N. Steinberg
  • Patent number: 4952494
    Abstract: An assay to detect the presence of live non-A, non-B hepatitis virus in vitro. Bone marrow cells are exposed to a body fluid or biological preparation to be tested and the cells are placed in suspension. When using bone marrow cells, growth factors are added to the bone marrow stem cells. Therefore, if the number of colonies growing in the mixture are less than that number present in the culture of cells exposed to a sample that has been determined to contain no live virus, live non-A, non-B hepatitis virus is present in the sample tested. The assay is particularly useful to determine the presence of live non-A, non-B, hepatitis virus in a vaccine.
    Type: Grant
    Filed: December 6, 1988
    Date of Patent: August 28, 1990
    Assignee: Beth Isreal Hospital Association
    Inventors: Jerome B. Zeldis, Robert P. Gale, Howard N. Steinberg